Non-small Cell Lung Carcinoma
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-22EMA Authorised: Lumykras (sotorasib) — Amgen Europe B.V.
Lumykras (sotorasib) has been authorised by EMA for non-small cell lung carcinoma under conditional approval.
-
EMA approval · 2026-07-15EMA Authorised: Rozlytrek (Entrectinib) — Roche Registration GmbH
The EMA authorises Rozlytrek (entrectinib) for cancer, including non-small cell lung carcinoma, under conditional approval.
-
CLINICAL_TRIALS trial_result · 2026-07-09Clinical Trial Results: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study of pegylated IL-10 (pegilodecakin) in adults with advanced solid tumors; results from a first-in-human trial assessing safety …
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) [Phase 2]
Phase 2 trial assessing biomarker-directed pembrolizumab-based combination therapy in advanced non-small cell lung cancer has completed with…
-
EMA approval · 2026-04-28EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer [Phase 2]
This Phase 2 clinical trial evaluates stereotactic body radiation therapy with or without nivolumab for patients with Stage I-IIA or recurre…
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: A Beta-only IL-2 ImmunoTherapY Study [Phase 1, Phase 2]
Medicennа Therapeutics is evaluating a beta-only IL-2 immunotherapy (MDNA11) in Phase 1/2 across multiple advanced solid tumors; recruitment…
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX [Phase 4]
Phase 4 clinical trial evaluating Pembrolizumab in metastatic non-small cell lung cancer patients expressing PD-L1 who have their own patien…
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Merestinib In Non-Small Cell Lung Cancer And Solid Tumors [Phase 2]
Phase 2 trial update for merestinib in non-small cell lung cancer and solid tumors; study terminated with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) [Phase 3]
Phase 3 trial update for epoetin alfa in advanced non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer [Phase 2]
Phase 2 trial evaluating biomarkers for nivolumab and ipilimumab and their combination in lung cancer.
-
CLINICAL_TRIALS trial_result · 2023-12-29Clinical Trial Update: SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating SHR-1701 in combination with Fluzoparib for non-small cell lung cancer (lung squamous cell carcinoma).
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) [Phase 3]
A Phase 3 trial evaluating durvalumab alone or with chemotherapy for advanced non-small cell lung cancer (NSCLC) is active/not recruiting wi…
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: Genetic Predictors of Benefit to Pembrolizumab [Phase 2]
Phase 2 trial investigating genetic predictors of benefit to pembrolizumab in non-small cell lung carcinoma; the study was terminated with r…
-
EMA approval · 2023-07-17EMA Authorised: Iressa (gefitinib) — AstraZeneca AB
Iressa (gefitinib) is authorised in the EU for non-small cell lung carcinoma (carcinoma, non-small-cell lung).
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Atezolizumab Immunotherapy in Patients With Advanced NSCLC [Phase 2]
Phase 2 clinical trial update of atezolizumab immunotherapy in patients with advanced non-small cell lung carcinoma; results posted after co…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer [Phase 3]
A phase 3 clinical trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment for EGFR-mutated advanced non-s…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) [Phase 2]
A Phase 2 clinical trial comparing immunotherapy with chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy [Phase 3]
Phase 3 trial comparing nivolumab plus chemotherapy or nivolumab plus ipilimumab versus chemotherapy in EGFR-mutant NSCLC after failure of 1…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy [Phase 3]
Phase 3 trial comparing atezolizumab to docetaxel in non-small cell lung cancer after platinum-based chemotherapy failure has completed.
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC [Phase 1, Phase 2]
A completed early-phase study evaluating erlotinib with or without entinostat (SNDX-275) in advanced non-small cell lung cancer.
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating DEB-BACE with sequential arotinib and tirelizumab for advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
A completed clinical trial evaluating the impact of afatinib on quality of life and symptom burden in Greek patients with advanced non-small…